SCHEMBL867945

SCHEMBL867945

O=C(O)Cc1cccc(Cl)c1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.57
CXCL8 P10145 5/20 0.54
PTGS2 P35354 4/20 0.54
TTR P02766 2/20 0.54
ABCB11 O95342 2/20 0.54
PTGS1 P23219 2/20 0.54
NR1I3 Q14994 2/20 0.54
AKR1B10 O60218 1/20 0.54
UGT1A9 O60656 1/20 0.54
TRPA1 O75762 1/20 0.54
MT-CO2 P00403 1/20 0.54
ALB P02768 1/20 0.54
UGT1A6 P19224 1/20 0.54
UGT1A1 P22309 1/20 0.54
CXCR1 P25024 1/20 0.54
ADRA1A P35348 1/20 0.54
AGTR2 P50052 1/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
NR1H4 Q96RI1 1/20 0.54
UGT1A7 Q9HAW7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1373839 0.98 AKR1B1 (0.55) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL30287815 0.83 P2RX7 (0.45) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL17328561 0.83 P2RX7 (0.45) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL14691047 0.83 P2RX7 (0.45) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL25246670 0.82 AKR1B1 (0.44) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL1438538 0.82 MAPT (0.45) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL2547244 0.82 AKR1B1 (0.63) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL723768 0.80 CXCL8 (0.56) AKR1B1CXCL8PTGS2TDP1
SCHEMBL29933245 0.79 CXCL8 (0.65) AKR1B1CXCL8PTGS2TTRABCB11
SCHEMBL194831 0.79 CXCL8 (0.65) AKR1B1CXCL8PTGS2TTRABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
EP-3114715-A1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS Siemens Aktiengesellschaft (DE) 2017-01-11 EP claimed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
US-20260092045-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2026-04-02 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS INC. (CA) 2026-01-20 US disclosed
US-20250185502-A1 ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT OSRAM OLED GMBH (DE) 2025-06-05 US disclosed
US-12302747-B2 Optoelectronic component, organic functional layer, and method for producing an optoelectronic component OSRAM OLED GMBH (DE) 2025-05-13 US disclosed
EP-4524133-A2 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2025-03-19 EP disclosed
EP-4193399-B1 ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2025-01-29 EP disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
US-20080255230-A1 THERAPEUTIC FLUOROETHYLCYANO GUANIDINES ALLERGAN, INC. 2008-10-16 US disclosed
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN, INC. 2008-10-16 US disclosed
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ALLERGHAN, INC. 2008-08-14 US disclosed
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ALLERGHAN, INC. 2008-08-14 US disclosed
US-20080004301-A1 Benzene Compound Having 2 or More Substituents DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-01-03 US disclosed
EP-1817282-A1 PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-08-15 EP disclosed
EP-1806332-A1 BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS Daiichi Sankyo Company, Limited (JP) 2007-07-11 EP disclosed
WO-2006056752-A1 PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, GAA AKR1B1 2133/4885CXCL8 4158/4885PTGS2 3908/4885
US-20080255230-A1 THERAPEUTIC FLUOROETHYLCYANO GUANIDINES PDE3A, PDE2A, PDE3B AKR1B1 3576/4885CXCL8 1525/4885PTGS2 1093/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN AKR1B1 224/4885CXCL8 3866/4885PTGS2 58/4885
US-20260092045-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS TFPI, F3, BTK AKR1B1 3925/4885CXCL8 2020/4885PTGS2 2473/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 AKR1B1 2334/4885CXCL8 4516/4885PTGS2 3923/4885
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2A, ADRA2C AKR1B1 1938/4885CXCL8 2265/4885PTGS2 780/4885
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2C, ADRA2A AKR1B1 336/4885CXCL8 3512/4885PTGS2 1703/4885
US-20080004301-A1 Benzene Compound Having 2 or More Substituents NR1H2, NR1H3, NCOR2 AKR1B1 588/4885CXCL8 3216/4885PTGS2 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.